Bevacizumab and Ovarian Cancer
Links shared publicly online about this topic
ASCO '11: Incorporating Bevacizumab into Ovarian Cancer Treatment -- Practical Considerations. http://dld.bz/ac4HS
asco.org — “ASCO '11: Incorporating Bevacizumab into Ovarian Cancer Treatment -- Practical Considerations. http://dld.bz/ac4HS” View full resource at asco.org
Most Recently Shared on June 7, 2011 at 7:15 pm By:
Paul Cacciatore Patient Advocate
ASCO '11: Incorporating Bevacizumab into Ovarian Cancer Treatment -- Practical Considerations. http://dld.bz/ac4HS
Medical News: Bevacizumab Slows Ovarian Cancer Progression - in Hematology/Oncology, Other Cancers from MedPage Today
medpagetoday.com — “Maintenance therapy with bevacizumab (Avastin) following combination therapy with the drug and chemotherapy improved progression-free survival in women with previously untreated advanced ovarian cance” View full resource at medpagetoday.com
Most Recently Shared on February 26, 2010 at 1:12 am By:
Bevacizumab Slows Ovarian Cancer Progression Maintenance therapy with bevacizumab (Avastin) following combination the.. http://bit.ly/andCCr
ingentaconnect Bevacizumab costly for ovarian cancer
ingentaconnect.com — “ingentaconnect Bevacizumab costly for ovarian cancer” View full resource at ingentaconnect.com
Most Recently Shared on March 23, 2011 at 3:08 am By:
Bevacizumab costly for ovarian cancer: (Source: PharmacoEconomics and Outcomes News)MedWorm Sponsor Message: Wat... http://bit.ly/f7ExB1
Bevacizumab (Avastin) and Ovarian Cancer | The Citizen Oncologist
citizenoncologist.com — “Bevacizumab (Avastin) and Ovarian Cancer | The Citizen Oncologist” View full resource at citizenoncologist.com
Most Recently Shared on December 30, 2011 at 3:10 pm By:
Frederick Tucker Oncologist, Physician, Doctor, Internist, and Psychiatrist
Ovarian cancer treatment shows promise. http://t.co/NyugE82h
Medical News: Bevacizumab Value in Ovarian Cancer Questioned - in Clinical Context, Ovarian Cancer from MedPage Today
medpagetoday.com — “The controversial targeted agent bevacizumab (Avastin) is not cost-effective for patients with advanced ovarian cancer, researchers reported.” View full resource at medpagetoday.com
Most Recently Shared on March 8, 2011 at 10:02 pm By:
Bevacizumab Value in Ovarian Cancer Questioned (CME/CE, with video) http://bit.ly/g4wKpl
Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer
onclive.com — “Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in PFS when bevacizumab was added to chemotherapy and continued as maintenance therapy.” View full resource at onclive.com
Most Recently Shared on July 27, 2011 at 7:45 pm By:
Bevacizumab Added to Chemotherapy Provides Meaningful Benefit in Recurrent Ovarian Cancer http://t.co/gLOIrDB
Bevacizumab extends progression-free survival in women with advanced ovarian cancer
news-medical.net — “Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.” View full resource at news-medical.net
Most Recently Shared on June 7, 2010 at 12:55 pm By:
Ovarian Cancer News: Bevacizumab extends progression-free survival in women with advanced ovarian cancer: Newly ... http://buzzup.com/zltp
Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer
news-medical.net — “Early results from a large Phase-III trial suggest that adding bevacizumab to chemotherapy as a treatment for newly diagnosed ovarian cancer reduces the risk of disease progression during the first year of treatment. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Tim Perren from Leeds Teaching Hospitals NHS Trust, UK, reported findings from the international ICON7 trial, which included 1528 women with high-risk early or advanced stage epithelial ovar” View full resource at news-medical.net
Most Recently Shared on October 12, 2010 at 3:08 am By:
Ovarian Cancer News: Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer: Early ... http://buzzup.com/1ceso
Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer
news-medical.net — “Early results from a large Phase-III trial suggest that adding bevacizumab to chemotherapy as a treatment for newly diagnosed ovarian cancer reduces the risk of disease progression during the first year of treatment. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Tim Perren from Leeds Teaching Hospitals NHS Trust, UK, reported findings from the international ICON7 trial, which included 1528 women with high-risk early or advanced stage epithelial ovar” View full resource at news-medical.net
Most Recently Shared on October 12, 2010 at 4:07 am By:
Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer: Early results from a large Pha... http://bit.ly/9CF99N
Bevacizumab Delays Disease Progression in Ovarian Cancer - QualityPoint Technologies
qualitypointtech.net — “Early results from a phase 3 trial add evidence that bevacizumab plus standard therapy reduces the risk for disease progression. Medscape Medical News” View full resource at qualitypointtech.net
Most Recently Shared on October 18, 2010 at 3:17 pm By:
Bevacizumab Delays Disease Progression in Ovarian Cancer: Early results from a phase 3 trial add evidence that bev... http://bit.ly/cxV7tR
Bevacizumab Halves Progression Risk in Recurrent Ovarian Cancer : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on June 5, 2011 at 11:58 pm By:
Miriam E. Tucker Patient Expert
RT @IntMedNews: Bevacizumab Halves Progression Risk in Recurrent Ovarian #Cancer http://bit.ly/ipBNsP
Does Bevacizumab Improve Outcomes in Advanced Ovarian Cancer? Video
vodpod.com — “Maurie Markman, M.D. (M.D. Anderson Cancer Ctr.) discusses important gynecologic abstracts to be presented at the 2010 Annual ASCO Mtg. to be held June 4-8, 2010. 04 June 10. : Dr. Maurie Markman previews the findings of the latest Gynecologic Oncology Group study as well as a provocative but preliminary study on the value of screening for ovarian cancer.” View full resource at vodpod.com
Most Recently Shared on June 4, 2010 at 4:47 pm By:
Paul Cacciatore Patient Advocate
Maurie Markman, M.D. (M.D. Anderson Cancer Ctr.) discusses important gynecologic abstracts to be presented at the 2010… http://bit.ly/a2FqDg
GOG-0218: Front-line, maintenance bevacizumab improved PFS in advanced ovarian cancers | HemOncToday
hemonctoday.com — “GOG-0218: Front-line, maintenance bevacizumab improved PFS in advanced ovarian cancers | HemOncToday” View full resource at hemonctoday.com
Most Recently Shared on June 6, 2010 at 4:19 pm By:
HemOnc Today Oncology and Health News
Bevacizumab with chemotherapy plus maintenance bevacizumab may be new standard for advanced ovarian cancer. #ASCO10 http://ht.ly/1UJ2p
Bevacizumab Effective With First-Line Treatment for Ovarian Cancer - OncologySTAT
oncologystat.com — “Bevacizumab Effective With First-Line Treatment for Ovarian Cancer - Elsevier Global Medical News. 2012 Jan 4, MA Moon” View full resource at oncologystat.com
Most Recently Shared on January 5, 2012 at 3:21 pm By:
OncologySTAT Health Site and Oncology
Story of the Week: Bevacizumab Effective With First-Line Treatment for Ovarian Cancer http://t.co/0usyy1dE
Bevacizumab Plus Chemotherapy May Improve Overall Survival In High-Risk Ovarian Cancer
onclive.com — “Concurrent and continued bevacizumab added to standard chemotherapy with carboplatin/ paclitaxel improved OS in women with high-risk ovarian cancer, according to an interim survival analysis of the ICON7 trial.” View full resource at onclive.com
Most Recently Shared on August 2, 2011 at 9:33 pm By:
Bevacizumab (Avastin) Plus Chemotherapy May Improve Overall Survival In High-Risk Ovarian Cancer http://t.co/fopeth1
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Paul Cacciatore
Founder of Libby's H*O*P*E* (*Helping *Ovarian Cancer Survivors *Persevere Through *Education)
-
medical_tweets
-
Ovarian Cancer OW
Organizing ovarian cancer resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
